Nurix Therapeutics (NRIX) Stock Statistics & Valuation Metrics

Nurix Therapeutics has a market cap or net worth of $2.84B. The enterprise value is $2.01B.

Nurix Therapeutics has 109,249,820 shares outstanding. The number of shares has decreased by -2.65% in one year.

Nurix Therapeutics’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -47.26%.

The current PE Ratio of Nurix Therapeutics is 10.4. Nurix Therapeutics’s PEG ratio is -0.94.

In the last 12 months, Nurix Therapeutics had revenue of 83.98M and earned -264.46M in profits. Earnings per share was -3.05.

In the last 12 months, operating cash flow was 379.31M and capital expenditures -9.50M, giving a free cash flow of 369.81M billion.

Nurix Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Nurix Therapeutics upcoming earnings date is Feb 17, 2027, After Close (Confirmed).

Nurix Therapeutics as a current ratio of 7.02, with Debt / Equity ratio of 6.75%

In the past 12 months, Nurix Therapeutics has paid 760.00K in taxes.

Nurix Therapeutics EV to EBITDA ratio is -5.20, with an EV/FCF ratio of -4.84.

Nurix Therapeutics has $1.05B in cash and marketable securities with $65.33M in debt, giving a net cash position of $982.92M billion.

Gross margin is 86.50%, with operating margin of -340.16%, and net profit margin of -314.90%.

The average price target for Nurix Therapeutics is $34.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy